Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | CES1 | P23141 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL830160 | 0.89 | CES1 (0.57) | TDP1CES1CA1CA2SRD5A2 | |
| SCHEMBL8759338 | 0.84 | MAPK1 (0.59) | TDP1CES1CA1CA2SRD5A2 | |
| SCHEMBL17527918 | 0.78 | MAPK1 (0.55) | TDP1CES1CA1CA2SRD5A2 | |
| SCHEMBL16925496 | 0.77 | TDP1 (0.65) | TDP1CES1CA1CA2SRD5A2 | |
| SCHEMBL819944 | 0.76 | TDP1 (0.64) | TDP1CES1CA1CA2SRD5A2 | |
| SCHEMBL254773 | 0.75 | CES1 (0.65) | TDP1CES1CA1CA2SRD5A2 | |
| 4-Nitrobenzoic Acid SCHEMBL43476 | 0.74 | TDP1 (1.00) | TDP1CES1CA1CA2SRD5A2 | |
| Terephthalic Acid SCHEMBL28023943 | 0.74 | TDP1 (1.00) | TDP1CES1CA1CA2SRD5A2 | |
| SCHEMBL1398000 | 0.74 | CES1 (0.64) | TDP1CES1CA1CA2SRD5A2 | |
| SCHEMBL10940236 | 0.74 | CES1 (0.64) | TDP1CES1CA1CA2SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120164210-A1 | PHOTODYNAMIC THERAPEUTIC AGENT HAVING CELL-SPECIFIC ACTIVE ACCUMULATION PROPERTIES | THE UNIVERSITY OF TOKYO | 2012-06-28 | — | — | US | disclosed |
| EP-2374825-A1 | PHOTODYNAMIC THERAPEUTIC AGENT SHOWING ACCUMULATION OF CELL-SPECIFIC FUNCTIONS | Keio University (JP) | 2011-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120164210-A1 | PHOTODYNAMIC THERAPEUTIC AGENT HAVING CELL-SPECIFIC ACTIVE ACCUMULATION PROPERTIES | CD47, CD44, EPCAM | TDP1 2688/4885CES1 3456/4885CA1 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.